Alan S. Go, MD

Alan S. Go, MD, is Assistant Director for Clinical Research and a Senior Physician at the Division of Research (DOR), Kaiser Permanente, Northern California. He is also an Associate Professor in the Departments of Epidemiology, Biostatistics, and Medicine at the University of California, San Francisco.

On a national level, Dr. Go is the recent Chair of the National Institutes of Health’s Health Service Organization and Delivery (HSOD) study section, which focuses on clinical epidemiology and health services/outcomes research. He is a member of the American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy Workgroup on Antithrombotic Therapy for Atrial Fibrillation, as well as the American College of Cardiology/American Heart Association Subcommitee on Atrial Fibrillation Database and Research Development. Dr. Go’s research interests include: cardiovascular health services research and clinical epidemiology; management and outcomes of atrial fibrillation; prevention and treatment of vascular and other complications associated with chronic kidney disease; genetic predictors of cardiovascular disease; and optimizing treatment and outcomes of cardiovascular and renal disease.

Current Positions:
Assistant Director for Clinical Research and
Research Scientist, Division of Research, Kaiser Permanente, Northern California
Senior Physician, The Permanente Medical Group
Associate Professor, Departments of Epidemiology and Biostatistics and Department of Medicine, University of California School of Medicine, San Francisco

Primary Research Interests:

	Cardiovascular health services research and clinical epidemiology
	Atrial fibrillation and stroke prevention: effectiveness and safety
	Chronic renal insufficiency/chronic kidney disease and cardiovascular complications
	Cardiovascular pharmacoepidemiology and pharmacogenomics
	Genetic factors influencing risk and severity of cardiovascular disease and response to therapies
	Management and outcomes of coronary disease and heart failure
	Racial/ethnic variation in treatment and outcomes in cardiovascular and renal disease

Current Research Projects:

	HMORN Cardiovascular Research Network (CVRN)
	Epidemiology of Anticoagulation in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
	Chronic Renal Insufficiency Cohort (CRIC) Study
	Epidemiology and Impact of Renal Insufficiency and Acute Renal Failure on Cardiovascular Events, Mortality, and Resource Utilization
	Hispanic Chronic Renal Insufficiency Cohort (HCRIC) Study
	Chronic Renal Insufficiency and Cognitive Decline
	Epidemiology and Outcomes of Anemia and Renal Insufficiency Complicating Heart Failure: The ANemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study
	Mortality, Atherosclerotic Vascular, and End-Stage Renal Disease Risk Factors In Chronic Kidney Disease (MAVERICK)
	Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology (ADVANCE): Clinical and Genetic Predictors of Myocardial Infarction in Coronary Disease
	RNA Expression Profiling and Severity of Chronic Heart Failure
	HMO Research Network Centers for Education and Research and Therapeutics (CERTs)

Completed Research Projects (partial listing):

	Comparative Effectiveness of β-blockers in Older Adults with Heart Failure for the HMO Research Network DEcIDE Center
	Epidemiology, Practice, Outcomes and Cost of Heart Failure in Managed Care (EPOCH)
	Removing Barriers Mediating Outcome Variation by Ethnicity in Coronary Heart Disease: The REMOVE CHD Study

Selected Publications:

	Go AS, Barron HV, Rundle AC, Ornato JP, Avins AL. Bundle-branch block and in-hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med 1998;129:690-7.
	Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34.
	Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2000;102:11-3.
	Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
	Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Impact of intensity of oral anticoagulation on stroke severity and stroke mortality in patients with nonvalvular atrial fibrillation. The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. N Engl J Med 2003;349:1019-26.
	Go AS, Hylek EM, Chang Y, Capra AM, Henault LE, Jensvold NG, Selby JV, Singer DE. Effectiveness and safety of anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trial results translate into clinical practice? The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2003;290:2685-92.
	Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
	Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):429S-56S.
	Hall YN, Hsu CY, Iribarren C, Darbinian J, McCulloch CE, Go AS. The conundrum of increased burden of end-stage renal disease in Asians. Kidney Int 2005;68:2310-6.
	Go AS, Fang MC, Singer DE. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis 2005; 48:108-24.
	Hsu CY, McCulloch CE, Darbinian J, Iribarren C, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-8.
	Hall YN, Hsu CY, Iribarren C, Darbinian J, McCulloch CE, Go AS. The conundrum of increased burden of end-stage renal disease in Asians. Kidney Int 2005;68:2310-6.
	Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, Hlatky MA; Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 2006;144:229-38.
	Rosamond W, Flegal K, Friday G, Furie K, Go AS, Greenlund K, Haase N, Ho M, Howard V, B. K, Kittner S, Lloyd-Jones DM, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld JS, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y, for the American Heart Association Statistics Committee and Stroke Statistics Committee. Heart Disease and Stroke Statistics--2007 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation published online December 28, 2006.
	Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006; 296:2105-11.